Form 4: Artelo Biosciences CEO Gorgas Reprices and Revests Stock Options
SEC Form 4
Gregory D. Gorgas, CEO of Artelo Biosciences, amends and reprices several stock option grants as part of a company-wide offer.
Summary
- Gregory D. Gorgas, the President, CEO, CFO, Treasurer, and Secretary of Artelo Biosciences, Inc., filed a Form 4 detailing changes in his beneficial ownership of the company's securities on February 28, 2024.
- The filing primarily concerns the repricing and revesting of several stock option grants held by Mr. Gorgas.
- These adjustments were made pursuant to a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors.
- The offer involved a one-time adjustment to reprice and adjust the vesting of certain eligible options.
- Specifically, the exercise prices of several options were adjusted to $1.55, and the vesting schedules were modified such that one-third of the shares vest on the first anniversary of the Amendment Date (February 28, 2024), with the remainder vesting monthly thereafter.
- Mr. Gorgas acquired new options at the $1.55 price and disposed of old options at prices ranging from $3.15 to $39.9.
Sentiment
Score: 6
Explanation: The sentiment is neutral. While repricing can be seen as positive for incentivizing management, it also raises questions about past performance and potential dilution.
Positives
- The repricing of stock options to $1.55 may incentivize the CEO to improve company performance.
- The revesting schedule aligns the CEO's interests with the long-term success of the company.
Negatives
- The repricing of stock options could be seen as a reward for past performance that may not have met expectations.
- The dilution of existing shareholders may occur if the options are exercised.
Risks
- The success of the company still depends on the execution of its business strategy.
- Market conditions and other external factors could impact the company's performance.
Industry Context
Repricing and revesting of stock options are common practices used by companies to incentivize executives, especially when the stock price has declined. This aligns management's interests with shareholders by providing an incentive to increase the stock price.
Comparison to Industry Standards
- Stock option repricing is a fairly common practice, especially among smaller biotech companies facing stock price volatility.
- Similar companies like Cassava Sciences and Anavex Life Sciences have also used stock options as a key component of executive compensation.
- The specific terms of the repricing (exercise price, vesting schedule) would need to be compared to industry benchmarks to determine if they are favorable or unfavorable to the executive and shareholders.
Stakeholder Impact
- Shareholders may experience dilution if the options are exercised.
- Employees may be affected by the company's overall performance, which is influenced by the CEO's incentives.
Key Dates
| Date | Description |
|---|---|
| August 29, 2019 | Original grant date of a stock option, later adjusted due to a reverse stock split. |
| February 12, 2021 | Original grant date of a stock option, later adjusted due to a reverse stock split. |
| March 5, 2021 | Original grant date of a stock option, later adjusted due to a reverse stock split. |
| December 3, 2021 | Original grant date of a stock option, later adjusted due to a reverse stock split. |
| August 10, 2022 | Date of a 1-for-15 reverse stock split, affecting previously granted stock options. |
| February 1, 2023 | Vesting Commencement Date for a stock option grant. |
| February 28, 2024 | Date of the repricing and revesting of stock options. |
| March 01, 2024 | Date of signature of the Form 4 filing. |
| August 29, 2029 | Expiration date of a stock option. |
| February 12, 2031 | Expiration date of a stock option. |
| March 05, 2031 | Expiration date of a stock option. |
| December 03, 2031 | Expiration date of a stock option. |
| February 01, 2033 | Expiration date of a stock option. |
Keywords
stock options, repricing, revesting, Form 4, Artelo Biosciences, Gorgas, CEO, ARTL
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.